Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

BMS And Scripps Join For Drug Discovery

by Michael McCoy
June 25, 2012 | A version of this story appeared in Volume 90, Issue 26

Bristol-Myers Squibb and Scripps Research Institute have entered a five-year pact to apply novel chemistry to drug discovery and synthesis. Under the agreement, Scripps investigators will prepare synthetic intermediates and analogs for biological evaluation against BMS targets. Separately, Scripps has licensed click chemistry developed by Nobel Laureate K. Barry Sharpless to Sutro Biopharma, a South San Francisco-based firm that will use the technology to synthesize therapeutic proteins.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.